Vaccine News and Research

Latest Vaccine News and Research

Reports highlight global state of TB epidemic, concerns over drug-resistant TB

Increasing rates of multidrug-resistant tuberculosis "are hampering world health programs aimed at tackling TB and threaten to wipe out progress made against the disease, scientists said on Friday," Reuters reports (Kelland, 3/18).

19 Mar 2011

BUSM professors highlight increased risks of naturally occurring infections

Paul Duprex, PhD, and Elke M-hlberger, PhD, both associate professors of microbiology at Boston University School of Medicine, recently co-authored a commentary about viruses for Microbiology Today, the monthly publication of the Society of General Microbiology, which is the largest microbiological society in Europe.

19 Mar 2011

Researchers identify protein that triggers immune response in TB-infected people

Scientists have discovered a protein secreted by tuberculosis bacteria that could be a promising new vaccine candidate, they report today in Proceedings of the National Academy of Sciences. The protein could also be used to improve diagnosis of TB.

19 Mar 2011

Commentary on the global challenges of emerging viral infections

Paul Duprex, PhD, and Elke Mühlberger, PhD, both associate professors of microbiology at Boston University School of Medicine (BUSM), recently co-authored a commentary about viruses for Microbiology Today, the monthly publication of the Society of General Microbiology, which is the largest microbiological society in Europe. The article focuses on the history of viruses and vaccines and gives their perspective on what is necessary to evolve to the next era of virology research.

18 Mar 2011

Modified mRNA raises hope for safe and effective cancer drugs

Modern gene therapies raise hopes of combating many diseases until now considered terminal. Nowadays, however, the methods are expensive and carry a risk of severe complications.

18 Mar 2011

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

18 Mar 2011

Liquid polymer research could represent next breakthrough in stem cell therapy

At present, cartilage implants created using stem cells can only be constructed as a solid shape, acting as an interim measure before the almost inevitable need for total joint replacement.

18 Mar 2011

Study sheds light on how vitamin A contributes to immune responses in gastrointestinal tract

Although it has been known for some time that vitamin A deficiency is linked with an impaired ability to resist infections, exactly how vitamin A and its metabolites contribute to the immune response is not well understood.

18 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

17 Mar 2011

Scientists to develop new universal vaccine against various flu viruses

A vaccine that helps against all types of influenza - for several years? If all goes right for Norwegian company Bionor Pharma ASA, such a vaccine could exist within a few years.

17 Mar 2011

Experts to discuss work directions for fight against TB at ITM conference in Antwerp

On occasion of the World TB Day, leading experts from 12 countries will take stock of the fight against tuberculosis, during a conference at the Institute of Tropical Medicine in Antwerp.

17 Mar 2011

EU parliament approves resolution calling for countries to revise pandemic response

On the heels of the release of a draft report by an independent panel of experts examining the WHO's response to H1N1, BMJ News reports on a recently approved resolution and accompanying report released by the European Union parliament that calls on EU countries to revise their flu prevention plans "to make them more effective, coherent, and flexible" and for the WHO to revise its definition of pandemic to take into account not only geographical spread of disease but also severity.

16 Mar 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

Medicago receives $3.8M as second milestone payment from U.S. DARPA for cGMP vaccine facility

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the second milestone payment of US$3.8 million from the Defense Advanced Research Projects Agency ("DARPA").

15 Mar 2011

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

OncoSec Medical Inc., a developer of innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs, announced today that it has signed an agreement with Inovio Pharmaceuticals, Inc. providing for the purchase by OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

15 Mar 2011

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford BioMedica plc, a leading gene therapy company, today announces that further analyses of the TroVax Renal Immunotherapy Survival Trial, a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

15 Mar 2011

Elevated p21 expression may block key steps in viral life cycle

Elevated levels of p21, a protein best known as a cancer fighter, may be involved in the ability of a few individuals to control HIV infection with their immune system alone.

15 Mar 2011

Global chronic disease burdens are increasing rapidly: Research

Those working for healthier humans around the globe are making headway in fighting communicable diseases such as AIDS, malaria and diarrheal illness, according to research from the Frederick S. Pardee Center for International Futures in the University of Denver's Josef Korbel School of International Studies.

15 Mar 2011

Vaccine News and Research

Latest Vaccine News and Research

Reports highlight global state of TB epidemic, concerns over drug-resistant TB

BUSM professors highlight increased risks of naturally occurring infections

Researchers identify protein that triggers immune response in TB-infected people

Commentary on the global challenges of emerging viral infections

Modified mRNA raises hope for safe and effective cancer drugs

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

Liquid polymer research could represent next breakthrough in stem cell therapy

Study sheds light on how vitamin A contributes to immune responses in gastrointestinal tract

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

Scientists to develop new universal vaccine against various flu viruses

Experts to discuss work directions for fight against TB at ITM conference in Antwerp

EU parliament approves resolution calling for countries to revise pandemic response

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Medicago receives $3.8M as second milestone payment from U.S. DARPA for cGMP vaccine facility

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Elevated p21 expression may block key steps in viral life cycle

Global chronic disease burdens are increasing rapidly: Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in